- Conditions
- GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis (MF), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML)
- Interventions
- Tacrolimus, Early Tacrolimus Taper Strategy
- Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Palo Alto, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
- Device · Combination Product
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- PET/MRI, Percutaneous ablation, Stereotactic body radiotherapy
- Device · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetic Foot Ulcer
- Interventions
- AMNIOEXCEL Plus Amniotic Membrane, A Marketed Comparator, Standard of Care
- Other · Device
- Lead sponsor
- Integra LifeSciences Corporation
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- Fresno, California • Los Angeles, California • Gainesville, Georgia + 3 more
- Conditions
- Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors, Malignant Rhabdoid Tumor (MRT), Rhabdoid Tumor of the Kidney (RTK), Epithelioid Sarcoma, Chordoma
- Interventions
- Tazemetostat, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Susan Chi, MD
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
- Interventions
- Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients, GVHD Regimen B: BM Recipients
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2031
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Orange, California • San Diego, California + 20 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent, Solid Tumor, Recurrent, Neuroblastoma, Recurrent, Refractory, Ewing Sarcoma, Recurrent, Refractory, Rhabdomyosarcoma, Recurrent, Refractory, Osteosarcoma, Recurrent, Refractory, Rhabdoid Tumor, Recurrent, Refractory
- Interventions
- Abemaciclib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia